Baidu
map

WCLC 2017:FLAURA研究伴随诊断结果公布:血浆EGFR突变阳性与组织阳性患者接受奥希替尼一线治疗获益一致

2017-10-18 佚名 肿瘤资讯

2017年10月15日-18日在日本海滨城市横滨,第18届世界肺癌大会正如火如荼地举行中。毫无疑问,本次WCLC中靶向治疗依旧是大家关注的话题。继一个月前FLAURA研究在ESMO大会上首次公布结果后,本次大会公布了FLAURA研究血浆ctDNA EGFR突变的检测结果和疗效数据分析。来自美国纽约纪念斯隆凯特琳癌症中心的Mark Kris以“All EGFR TKIs are not the sa

2017年10月15日-18日在日本海滨城市横滨,第18届世界肺癌大会正如火如荼地举行中。毫无疑问,本次WCLC中靶向治疗依旧是大家关注的话题。继一个月前FLAURA研究在ESMO大会上首次公布结果后,本次大会公布了FLAURA研究血浆ctDNA EGFR突变的检测结果和疗效数据分析。来自美国纽约纪念斯隆凯特琳癌症中心的Mark Kris以“All EGFR TKIs are not the same”为题进行专场点评。

FLAURA研究血浆 ct DNA 分析结果

WCLC会议现场,来自美国的Jhanelle Gray教授代表FLAURA研究团队,报道了本研究中血浆与肿瘤组织检测EGFR突变的一致性以及基于血浆EGFR突变检测结果的疗效分析数据。

FLAURA研究是一项III期,双盲的随机对照临床研究,评估奥希替尼对比标准的EGFR TKI用于EGFR突变的晚期NSCLC一线治疗。结果显示,组织EGFR突变阳性的晚期NSCLC患者,奥希替尼对比标准一线治疗可以显着延长PFS(18.9 vs 10.2个月),降低疾病进展风险((HR=0.46;95%CI:0.37-0.57),P<0.0001)。

FLAURA研究方案中有一个次要终点指标为根据血浆EGFR突变状态,评估奥希替尼治疗的PFS。本次的WCLC会议上,研究者公布了这一结果。研究回顾性的进行血浆ctDNA的EGFR突变检测(采用cobas EGFR突变检测v2),评估了组织和血浆检测EGFR突变的一致性(Exon 19del/L858R),并基于基线血浆EGFR突变状态评估评估奥希替尼治疗的PFS。

结果:全球共556例患者参与随机,定义为全分析集(FAS集),其中奥希替尼组279例,标准治疗组277例。对所有入组患者进行血浆分析,血浆ctDNA EGFR突变阳性的患者359例(65%),阴性的患者124例(22%),无法确定突变结果的患者73例(13%)。

进一步分析肿瘤组织和血浆EGFR突变检测的一致性,结果显示两者具有较好的一致性,对于19外显子缺失突变,一致率为87%;对于L858R点突变,一致率为88%。

在血浆EGFR突变阳性人群中,奥希替尼与标准EGFR-TKI相比,疾病进展风险降低了56%(HR=0.44,95% CI 0.34, 0.57),PFS与全分析集(FAS集)中奥希替尼对比标准治疗的结果相似。

此外,在血浆EGFR突变阴性的患者中(n=124例),奥希替尼组(n=60)亦显着优于标准治疗组(n=64),HR=0.48(95%CI:0.28-0.80)。

进一步分析两组患者的ORR,结果显示,在FAS集中,无论是奥希替尼组还是标准治疗组,都取得了较高的ORR,分别为80%和76%。此外,血浆ctDNA EGFR突变阳性和阴性的患者,ORR结果和FAS集中一致。

这一研究结果对于首诊的晚期非小细胞肺癌(NSCLC)患者无疑是个福音,血浆EGFR突变检测与肿瘤组织检测相比,具有高度的一致性和显着的治疗获益,说明我们可以采用血浆EGFR突变的结果来选择EGFR TKI。显然,这让临床上很多无法获取组织标本的患者,也能够进行EGFR突变检测,可以预见,临床上会有更多的EGFR突变患者被发现,进而从EGFR-TKI治疗中获益。在最后的总结中,Jhanelle Gray教授指出,这一研究结果支持临床上根据血浆EGFR突变结果,来选择接受一线奥希替尼治疗的患者。

Mark Kris教授现场点评“All EGFR TKIs are not the same”

来自美国纽约纪念斯隆凯特琳癌症中心的Mark Kris以“All EGFR TKIs are not the same”为题进行专场点评。

FLAURA研究表明,奥希替尼在安全性和疗效性方面,均显着优于标准治疗,应该作为一线治疗的首选。可以说,FLAURA研究的结果再一次改变了临床实践指南。2017年9月,美国国立综合癌症网络(NCCN)肿瘤临床实施指南已经推荐奥希替尼用于局部晚期或转移性EGFR突变阳性NSCLC患者的一线治疗。就在几天前,FDA授予奥希替尼(osimertinib,Tagrisso)用于一线治疗转移性EGFR突变阳性非小细胞肺癌(NSCLC)患者的“突破性疗法”称号,相信FDA也会很快批准奥希替尼一线治疗局部晚期或转移性EGFR突变阳性NSCLC患者的适应症。

在谈到临床该如何选择用药时间时,Mark Kris教授指出,目前我们已经有了很多个EGFR TKI可供选择,如何更好地排兵布阵对临床医生们提出了越来越大的挑战。“All EGFR TKIs are not the same”,每一个EGFR TKI都有各自的特点。是不是所有的患者都应该选用最好的TKI呢?其实不然,作为肿瘤医生,我们应该对每一个药物的特征了如指掌,并结合每个患者的具体情况,来做出最佳的决策。

血浆分析结果显示,ctDNA EGFR突变阳性和肿瘤组织EGFR突变阳性的患者,接受奥希替尼治疗的疗效一致,说明血浆EGFR突变阳性的患者,可以推荐其接受奥希替尼治疗。然而,血浆检测仍然存在相对低敏感性的缺陷,因此血浆EGFR突变阴性的患者,仍需进行组织检测。需要思考的是,如果采用血浆检测先行的策略,对于这部分患者,势必会造成治疗的延误。此外,我们目前正处于一个多基因检测的时代,越来越多的驱动基因被发现,临床检测正逐步从单基因过渡到多基因同步检测,未来NGS检测或许会成为新的检测标准。但是组织和血浆NGS检测结果的一致性如何,仍需更多研究的探索。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2004385, encodeId=1b9f2004385c4, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Jul 18 10:45:00 CST 2018, time=2018-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813057, encodeId=fce7181305e88, content=<a href='/topic/show?id=4cc9916457c' target=_blank style='color:#2F92EE;'>#诊断结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91645, encryptionId=4cc9916457c, topicName=诊断结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Wed Jan 10 23:45:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956432, encodeId=2d8b1956432b3, content=<a href='/topic/show?id=326f2610414' target=_blank style='color:#2F92EE;'>#伴随诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26104, encryptionId=326f2610414, topicName=伴随诊断)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/fa8I6JticHgohY5FSGE98I1F4gpCjrpl2nbN6jZJY6JEqAjUibjItOA9AsgbBwTuBzAPbU5Tl8DxfemWUFFzBOYw/132, createdBy=24c12500054, createdName=ms2186806800017884, createdTime=Tue May 29 04:45:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940503, encodeId=74ae1940503ed, content=<a href='/topic/show?id=a983e49197' target=_blank style='color:#2F92EE;'>#FLAURA研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7491, encryptionId=a983e49197, topicName=FLAURA研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Apr 26 02:45:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803539, encodeId=c72018035394d, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75519, encryptionId=0b3fe551971, topicName=突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Sun Sep 09 20:45:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040491, encodeId=0ce22040491ac, content=<a href='/topic/show?id=8289e49017' target=_blank style='color:#2F92EE;'>#FLAURA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7490, encryptionId=8289e49017, topicName=FLAURA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Tue Feb 13 05:45:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785088, encodeId=993c1e850881a, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6599, encryptionId=0b4f65992c, topicName=EGFR突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Wed Jul 04 16:45:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412339, encodeId=c4a81412339d5, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18637, encryptionId=de711863ed3, topicName=WCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91252863770, createdName=木头人514, createdTime=Fri Oct 20 01:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534344, encodeId=26161534344c4, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Fri Oct 20 01:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2004385, encodeId=1b9f2004385c4, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Jul 18 10:45:00 CST 2018, time=2018-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813057, encodeId=fce7181305e88, content=<a href='/topic/show?id=4cc9916457c' target=_blank style='color:#2F92EE;'>#诊断结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91645, encryptionId=4cc9916457c, topicName=诊断结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Wed Jan 10 23:45:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956432, encodeId=2d8b1956432b3, content=<a href='/topic/show?id=326f2610414' target=_blank style='color:#2F92EE;'>#伴随诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26104, encryptionId=326f2610414, topicName=伴随诊断)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/fa8I6JticHgohY5FSGE98I1F4gpCjrpl2nbN6jZJY6JEqAjUibjItOA9AsgbBwTuBzAPbU5Tl8DxfemWUFFzBOYw/132, createdBy=24c12500054, createdName=ms2186806800017884, createdTime=Tue May 29 04:45:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940503, encodeId=74ae1940503ed, content=<a href='/topic/show?id=a983e49197' target=_blank style='color:#2F92EE;'>#FLAURA研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7491, encryptionId=a983e49197, topicName=FLAURA研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Apr 26 02:45:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803539, encodeId=c72018035394d, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75519, encryptionId=0b3fe551971, topicName=突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Sun Sep 09 20:45:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040491, encodeId=0ce22040491ac, content=<a href='/topic/show?id=8289e49017' target=_blank style='color:#2F92EE;'>#FLAURA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7490, encryptionId=8289e49017, topicName=FLAURA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Tue Feb 13 05:45:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785088, encodeId=993c1e850881a, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6599, encryptionId=0b4f65992c, topicName=EGFR突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Wed Jul 04 16:45:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412339, encodeId=c4a81412339d5, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18637, encryptionId=de711863ed3, topicName=WCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91252863770, createdName=木头人514, createdTime=Fri Oct 20 01:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534344, encodeId=26161534344c4, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Fri Oct 20 01:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2004385, encodeId=1b9f2004385c4, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Jul 18 10:45:00 CST 2018, time=2018-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813057, encodeId=fce7181305e88, content=<a href='/topic/show?id=4cc9916457c' target=_blank style='color:#2F92EE;'>#诊断结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91645, encryptionId=4cc9916457c, topicName=诊断结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Wed Jan 10 23:45:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956432, encodeId=2d8b1956432b3, content=<a href='/topic/show?id=326f2610414' target=_blank style='color:#2F92EE;'>#伴随诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26104, encryptionId=326f2610414, topicName=伴随诊断)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/fa8I6JticHgohY5FSGE98I1F4gpCjrpl2nbN6jZJY6JEqAjUibjItOA9AsgbBwTuBzAPbU5Tl8DxfemWUFFzBOYw/132, createdBy=24c12500054, createdName=ms2186806800017884, createdTime=Tue May 29 04:45:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940503, encodeId=74ae1940503ed, content=<a href='/topic/show?id=a983e49197' target=_blank style='color:#2F92EE;'>#FLAURA研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7491, encryptionId=a983e49197, topicName=FLAURA研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Apr 26 02:45:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803539, encodeId=c72018035394d, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75519, encryptionId=0b3fe551971, topicName=突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Sun Sep 09 20:45:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040491, encodeId=0ce22040491ac, content=<a href='/topic/show?id=8289e49017' target=_blank style='color:#2F92EE;'>#FLAURA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7490, encryptionId=8289e49017, topicName=FLAURA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Tue Feb 13 05:45:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785088, encodeId=993c1e850881a, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6599, encryptionId=0b4f65992c, topicName=EGFR突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Wed Jul 04 16:45:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412339, encodeId=c4a81412339d5, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18637, encryptionId=de711863ed3, topicName=WCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91252863770, createdName=木头人514, createdTime=Fri Oct 20 01:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534344, encodeId=26161534344c4, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Fri Oct 20 01:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2004385, encodeId=1b9f2004385c4, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Jul 18 10:45:00 CST 2018, time=2018-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813057, encodeId=fce7181305e88, content=<a href='/topic/show?id=4cc9916457c' target=_blank style='color:#2F92EE;'>#诊断结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91645, encryptionId=4cc9916457c, topicName=诊断结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Wed Jan 10 23:45:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956432, encodeId=2d8b1956432b3, content=<a href='/topic/show?id=326f2610414' target=_blank style='color:#2F92EE;'>#伴随诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26104, encryptionId=326f2610414, topicName=伴随诊断)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/fa8I6JticHgohY5FSGE98I1F4gpCjrpl2nbN6jZJY6JEqAjUibjItOA9AsgbBwTuBzAPbU5Tl8DxfemWUFFzBOYw/132, createdBy=24c12500054, createdName=ms2186806800017884, createdTime=Tue May 29 04:45:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940503, encodeId=74ae1940503ed, content=<a href='/topic/show?id=a983e49197' target=_blank style='color:#2F92EE;'>#FLAURA研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7491, encryptionId=a983e49197, topicName=FLAURA研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Apr 26 02:45:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803539, encodeId=c72018035394d, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75519, encryptionId=0b3fe551971, topicName=突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Sun Sep 09 20:45:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040491, encodeId=0ce22040491ac, content=<a href='/topic/show?id=8289e49017' target=_blank style='color:#2F92EE;'>#FLAURA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7490, encryptionId=8289e49017, topicName=FLAURA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Tue Feb 13 05:45:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785088, encodeId=993c1e850881a, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6599, encryptionId=0b4f65992c, topicName=EGFR突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Wed Jul 04 16:45:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412339, encodeId=c4a81412339d5, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18637, encryptionId=de711863ed3, topicName=WCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91252863770, createdName=木头人514, createdTime=Fri Oct 20 01:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534344, encodeId=26161534344c4, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Fri Oct 20 01:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2004385, encodeId=1b9f2004385c4, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Jul 18 10:45:00 CST 2018, time=2018-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813057, encodeId=fce7181305e88, content=<a href='/topic/show?id=4cc9916457c' target=_blank style='color:#2F92EE;'>#诊断结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91645, encryptionId=4cc9916457c, topicName=诊断结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Wed Jan 10 23:45:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956432, encodeId=2d8b1956432b3, content=<a href='/topic/show?id=326f2610414' target=_blank style='color:#2F92EE;'>#伴随诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26104, encryptionId=326f2610414, topicName=伴随诊断)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/fa8I6JticHgohY5FSGE98I1F4gpCjrpl2nbN6jZJY6JEqAjUibjItOA9AsgbBwTuBzAPbU5Tl8DxfemWUFFzBOYw/132, createdBy=24c12500054, createdName=ms2186806800017884, createdTime=Tue May 29 04:45:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940503, encodeId=74ae1940503ed, content=<a href='/topic/show?id=a983e49197' target=_blank style='color:#2F92EE;'>#FLAURA研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7491, encryptionId=a983e49197, topicName=FLAURA研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Apr 26 02:45:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803539, encodeId=c72018035394d, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75519, encryptionId=0b3fe551971, topicName=突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Sun Sep 09 20:45:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040491, encodeId=0ce22040491ac, content=<a href='/topic/show?id=8289e49017' target=_blank style='color:#2F92EE;'>#FLAURA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7490, encryptionId=8289e49017, topicName=FLAURA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Tue Feb 13 05:45:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785088, encodeId=993c1e850881a, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6599, encryptionId=0b4f65992c, topicName=EGFR突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Wed Jul 04 16:45:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412339, encodeId=c4a81412339d5, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18637, encryptionId=de711863ed3, topicName=WCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91252863770, createdName=木头人514, createdTime=Fri Oct 20 01:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534344, encodeId=26161534344c4, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Fri Oct 20 01:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2004385, encodeId=1b9f2004385c4, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Jul 18 10:45:00 CST 2018, time=2018-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813057, encodeId=fce7181305e88, content=<a href='/topic/show?id=4cc9916457c' target=_blank style='color:#2F92EE;'>#诊断结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91645, encryptionId=4cc9916457c, topicName=诊断结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Wed Jan 10 23:45:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956432, encodeId=2d8b1956432b3, content=<a href='/topic/show?id=326f2610414' target=_blank style='color:#2F92EE;'>#伴随诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26104, encryptionId=326f2610414, topicName=伴随诊断)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/fa8I6JticHgohY5FSGE98I1F4gpCjrpl2nbN6jZJY6JEqAjUibjItOA9AsgbBwTuBzAPbU5Tl8DxfemWUFFzBOYw/132, createdBy=24c12500054, createdName=ms2186806800017884, createdTime=Tue May 29 04:45:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940503, encodeId=74ae1940503ed, content=<a href='/topic/show?id=a983e49197' target=_blank style='color:#2F92EE;'>#FLAURA研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7491, encryptionId=a983e49197, topicName=FLAURA研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Apr 26 02:45:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803539, encodeId=c72018035394d, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75519, encryptionId=0b3fe551971, topicName=突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Sun Sep 09 20:45:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040491, encodeId=0ce22040491ac, content=<a href='/topic/show?id=8289e49017' target=_blank style='color:#2F92EE;'>#FLAURA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7490, encryptionId=8289e49017, topicName=FLAURA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Tue Feb 13 05:45:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785088, encodeId=993c1e850881a, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6599, encryptionId=0b4f65992c, topicName=EGFR突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Wed Jul 04 16:45:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412339, encodeId=c4a81412339d5, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18637, encryptionId=de711863ed3, topicName=WCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91252863770, createdName=木头人514, createdTime=Fri Oct 20 01:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534344, encodeId=26161534344c4, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Fri Oct 20 01:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2004385, encodeId=1b9f2004385c4, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Jul 18 10:45:00 CST 2018, time=2018-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813057, encodeId=fce7181305e88, content=<a href='/topic/show?id=4cc9916457c' target=_blank style='color:#2F92EE;'>#诊断结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91645, encryptionId=4cc9916457c, topicName=诊断结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Wed Jan 10 23:45:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956432, encodeId=2d8b1956432b3, content=<a href='/topic/show?id=326f2610414' target=_blank style='color:#2F92EE;'>#伴随诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26104, encryptionId=326f2610414, topicName=伴随诊断)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/fa8I6JticHgohY5FSGE98I1F4gpCjrpl2nbN6jZJY6JEqAjUibjItOA9AsgbBwTuBzAPbU5Tl8DxfemWUFFzBOYw/132, createdBy=24c12500054, createdName=ms2186806800017884, createdTime=Tue May 29 04:45:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940503, encodeId=74ae1940503ed, content=<a href='/topic/show?id=a983e49197' target=_blank style='color:#2F92EE;'>#FLAURA研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7491, encryptionId=a983e49197, topicName=FLAURA研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Apr 26 02:45:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803539, encodeId=c72018035394d, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75519, encryptionId=0b3fe551971, topicName=突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Sun Sep 09 20:45:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040491, encodeId=0ce22040491ac, content=<a href='/topic/show?id=8289e49017' target=_blank style='color:#2F92EE;'>#FLAURA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7490, encryptionId=8289e49017, topicName=FLAURA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Tue Feb 13 05:45:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785088, encodeId=993c1e850881a, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6599, encryptionId=0b4f65992c, topicName=EGFR突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Wed Jul 04 16:45:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412339, encodeId=c4a81412339d5, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18637, encryptionId=de711863ed3, topicName=WCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91252863770, createdName=木头人514, createdTime=Fri Oct 20 01:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534344, encodeId=26161534344c4, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Fri Oct 20 01:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2004385, encodeId=1b9f2004385c4, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Jul 18 10:45:00 CST 2018, time=2018-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813057, encodeId=fce7181305e88, content=<a href='/topic/show?id=4cc9916457c' target=_blank style='color:#2F92EE;'>#诊断结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91645, encryptionId=4cc9916457c, topicName=诊断结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Wed Jan 10 23:45:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956432, encodeId=2d8b1956432b3, content=<a href='/topic/show?id=326f2610414' target=_blank style='color:#2F92EE;'>#伴随诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26104, encryptionId=326f2610414, topicName=伴随诊断)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/fa8I6JticHgohY5FSGE98I1F4gpCjrpl2nbN6jZJY6JEqAjUibjItOA9AsgbBwTuBzAPbU5Tl8DxfemWUFFzBOYw/132, createdBy=24c12500054, createdName=ms2186806800017884, createdTime=Tue May 29 04:45:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940503, encodeId=74ae1940503ed, content=<a href='/topic/show?id=a983e49197' target=_blank style='color:#2F92EE;'>#FLAURA研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7491, encryptionId=a983e49197, topicName=FLAURA研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Apr 26 02:45:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803539, encodeId=c72018035394d, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75519, encryptionId=0b3fe551971, topicName=突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Sun Sep 09 20:45:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040491, encodeId=0ce22040491ac, content=<a href='/topic/show?id=8289e49017' target=_blank style='color:#2F92EE;'>#FLAURA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7490, encryptionId=8289e49017, topicName=FLAURA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Tue Feb 13 05:45:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785088, encodeId=993c1e850881a, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6599, encryptionId=0b4f65992c, topicName=EGFR突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Wed Jul 04 16:45:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412339, encodeId=c4a81412339d5, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18637, encryptionId=de711863ed3, topicName=WCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91252863770, createdName=木头人514, createdTime=Fri Oct 20 01:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534344, encodeId=26161534344c4, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Fri Oct 20 01:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=)]
    2017-10-20 木头人514
  9. [GetPortalCommentsPageByObjectIdResponse(id=2004385, encodeId=1b9f2004385c4, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Jul 18 10:45:00 CST 2018, time=2018-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813057, encodeId=fce7181305e88, content=<a href='/topic/show?id=4cc9916457c' target=_blank style='color:#2F92EE;'>#诊断结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91645, encryptionId=4cc9916457c, topicName=诊断结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Wed Jan 10 23:45:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956432, encodeId=2d8b1956432b3, content=<a href='/topic/show?id=326f2610414' target=_blank style='color:#2F92EE;'>#伴随诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26104, encryptionId=326f2610414, topicName=伴随诊断)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/fa8I6JticHgohY5FSGE98I1F4gpCjrpl2nbN6jZJY6JEqAjUibjItOA9AsgbBwTuBzAPbU5Tl8DxfemWUFFzBOYw/132, createdBy=24c12500054, createdName=ms2186806800017884, createdTime=Tue May 29 04:45:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940503, encodeId=74ae1940503ed, content=<a href='/topic/show?id=a983e49197' target=_blank style='color:#2F92EE;'>#FLAURA研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7491, encryptionId=a983e49197, topicName=FLAURA研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Apr 26 02:45:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803539, encodeId=c72018035394d, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75519, encryptionId=0b3fe551971, topicName=突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Sun Sep 09 20:45:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040491, encodeId=0ce22040491ac, content=<a href='/topic/show?id=8289e49017' target=_blank style='color:#2F92EE;'>#FLAURA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7490, encryptionId=8289e49017, topicName=FLAURA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Tue Feb 13 05:45:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785088, encodeId=993c1e850881a, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6599, encryptionId=0b4f65992c, topicName=EGFR突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Wed Jul 04 16:45:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412339, encodeId=c4a81412339d5, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18637, encryptionId=de711863ed3, topicName=WCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91252863770, createdName=木头人514, createdTime=Fri Oct 20 01:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534344, encodeId=26161534344c4, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Fri Oct 20 01:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=)]
    2017-10-20 liuyiping
Baidu
map
Baidu
map
Baidu
map